3-formyl-indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-formyl-indole
• 英文别名: indoline-3-carbaldehyde；2,3-dihydro-1H-indole-3-carbaldehyde
• 化学式: C₉H₉NO
• mdl: MFCD19220335
• 分子量: 147.177
• InChiKey: NBKQRVSGHYZUOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-2-(methylthio)pyrimidine-5-carbohydrazide 、 3-formyl-indole 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以87%的产率得到4-chloro-N'-(indolin-3-ylmethylene)-2-(methylthio)pyrimidine-5-carbohydrazide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Some New Hydrazone Derivatives Bearing Pyrimidine Ring as Analgesic and Anti-Inflammatory Agents

  摘要：

  New hydrazone derivatives were synthesized from 4-chloro-2-(methylthio) pyrimidine-5-carbohydrazide. IR, 1H-NMR, 13C-NMR, mass spectral data and elemental analysis characterized synthesized compounds. All compounds were investigated for analgesic and anti-inflammatory activity with hot plate test and biochemical assay, respectively. The results of anti-inflammatory activity showed that compound 2t had maximal lipoxygenase (LOX) inhibition (66.30%) whereas inhibitions of 2a, 2c, 2i, 2k, 2l, 2m, 2p, 2s, and 2u were observed between approximately 45-15%. Our results also indicated that 15 compounds of 21 had an analgesic effect in hot plate test. Analgesic effect of 2l, 2s, 2t began earlier than others while the effect of 2i began at the latest time. According to the activity results, compound 2t have both significant analgesic and anti-inflammatory effects.

  DOI：

  10.32383/appdr/86743

文献信息

• [EN] 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS<br/>[FR] DERIVES DE L'ACIDE 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIQUE EN TANT QU'ANTAGONISTES DE CRTH2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2006021418A1

  公开（公告）日：2006-03-02

  The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent 'chemoattractant receptor-homologous molecule expressed on Th2 cells' antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.

  这项发明涉及2-硫代基苯并咪唑-1-基乙酸衍生物及其在治疗前列腺素介导的疾病中作为强效“趋化受体同源分子在Th2细胞上表达”的拮抗剂的用途，涉及含有这些衍生物的药物组合物以及其制备方法。
• Simple Protocol for the Knoevenagel Condensation Under Solvent Free Conditions using Tungstophosphoric Acid as Catalyst
  作者：Abdulrahman I. Alharthi

  DOI：10.14233/ajchem.2019.22072

  日期：2019.9.10

  The effect of calcination on the performance of tungstophosphoric acid for the product of Knoevenagel condensation was investigated. Substituted aldehydes and dimedone has been used in the presence of calcined tungstophosphoric acid as a heterogeneous catalyst using grinding method at room temperature. The results of reactions revealed that calcined tungstophosphoric acid has superior catalytic activity comparing to non-calcined catalyst in terms of yield and reaction time. Maximum yield of model compound was achieved by using 10 mol% of calcined catalyst in a reaction time that does not exceed 10 min, whereas the yield at same amount of non-calcined catalyst was 86 % in a reaction time of 35 min.

  针对钨磷酸钠在Knoevenagel缩合产物性能上的影响进行了煅烧研究。在室温下，使用煅烧的钨磷酸钠作为异相催化剂，采用研磨法，使用取代醛和二甲二酮进行了实验。实验结果表明，与未经煅烧的催化剂相比，煅烧的钨磷酸钠在产量和反应时间方面具有更优越的催化活性。在反应时间不超过10分钟的情况下，使用10%的煅烧催化剂可以获得模型化合物的最大产量，而在相同量的未煅烧催化剂下，反应时间为35分钟时产量为86%。
• [EN] HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES POUR MODULER LES CANAUX CALCIQUES
  申请人：VERTEX PHARMA

  公开号：WO2006010008A1

  公开（公告）日：2006-01-26

  Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions.

  杂环衍生物作为钙通道拮抗剂。这些组合物对治疗或缓解钙通道介导的疾病状况有用。
• [EN] N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS<br/>[FR] CARBOXAMIDES HETERO-BICYCLIQUES SUBSTITUES PAR N-AZABICYCLO, UTILISES EN TANT QU'AGONISTES DU RECEPTEUR DE L'ACETYLCHOLINE NICOTINIQUE
  申请人：UPJOHN CO

  公开号：WO2003037896A1

  公开（公告）日：2003-05-08

  The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W0 is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供式(I)的化合物，其中Azabicyclo为I、II、III、IV、V或VI；W0为双环基团，可为(a)、(b)或(c)。这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物形式，并且在已知α7参与的药物中是有用的。
• Methods of treating alzheimer's disease
  申请人：Schostarez Heinrich

  公开号：US20050130941A1

  公开（公告）日：2005-06-16

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R 1 -R 9 are defined herein.

  本发明涉及使用式(I)中变量R1-R9所定义的肼化合物治疗阿尔茨海默病和其他疾病，抑制β-分泌酶酶活性，抑制A beta肽在哺乳动物体内的沉积。